N calculation for trial about PK superiority [Power / Sample Size]

posted by dshah  – India/United Kingdom, 2022-09-02 13:52 (545 d 10:13 ago) – Posting: # 23262
Views: 2,020

Hi Alex!

I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
22,916 posts in 4,807 threads, 1,645 registered users;
34 visitors (0 registered, 34 guests [including 12 identified bots]).
Forum time: 23:05 CET (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5